Enochian Biosciences Inc. (NASDAQ:ENOB) shares traded 15.66% higher at $0.58 on Wall Street last session.
ENOB stock price is now -30.37% away from the 50-day moving average and -53.80% away from the 200-day moving average. The market capitalization of the company currently stands at $32.52M.
A total of 58.06% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ENOB stock. A new stake in Enochian Biosciences Inc. shares was purchased by NATIXIS during the first quarter worth $35,000. HRT FINANCIAL LP invested $22,000 in shares of ENOB during the first quarter. In the first quarter, GOLDMAN SACHS GROUP INC acquired a new stake in Enochian Biosciences Inc. valued at approximately $8,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in ENOB for approximately $8,000. WELLS FARGO & COMPANY/MN purchased a new stake in ENOB valued at around $2,000 in the second quarter.
Enochian Biosciences Inc. (NASDAQ: ENOB) opened at $0.5791 on Wednesday. During the past 12 months, Enochian Biosciences Inc. has had a low of $0.39 and a high of $2.99. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 0.30, and a quick ratio of 0.30. The fifty day moving average price for ENOB is $0.8193 and a two-hundred day moving average price translates $1.2444 for the stock.
The latest earnings results from Enochian Biosciences Inc. (NASDAQ: ENOB) was released for Mar, 2023. The company reported revenue of $4.06 million for the quarter, compared to $4.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.69 percent.
Enochian Biosciences Inc.(ENOB) Company Profile
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company’s product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
